Overview


According to FutureWise analysis the market for Viral Vectors and Plasmid DNA Manufacturing in 2023 is US$ 5.5 billion, and is expected to reach US$ 21.27 billion by 2031 at a CAGR of 18.40%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Viral Vectors and Plasmid DNA Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Cobra Biologics Ltd.
  • Brammer Bio
  • Waisman Biomanufacturing
  • Genezen
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  • Novasep Holding S.A.S
  • ATVIO Biotech Ltd
  • Vigene Biosciences, Inc.
  • General Electric Company (GE Healthcare)
  • CEVEC Pharmaceuticals GmbH
  • Batavia Biosciences B.V.
  • Biovian Oy
  • Wuxi AppTec Co., Ltd.
  • VGXI, Inc
  • Paragon Bioservices, Inc
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • VIVEbiotech S.L.
  • Creative Biogene
  • Vibalogics GmbH

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Vector Type

  • Adenovirus
  • Retrovirus
  • Plasmid DNA
  • AAV
  • Lentivirus
  • Others

By Workflow

  • Upstream Processing
    • Vector Amplification and Expansion
    • Vector Recovery/Harvesting
  • Downstream Processing
    • Purification
    • Fill-finish

By Application

  • Antisense and RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology

By Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

By End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, By Workflow, By Application, By Disease, By End-use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Viral Vectors and Plasmid DNA Manufacturing Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Viral Vectors and Plasmid DNA Manufacturing Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Viral Vectors and Plasmid DNA Manufacturing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Adenovirus
        2. Retrovirus
        3. Plasmid DNA
        4. AAV
        5. Lentivirus
        6. Others

  • 8.   Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Upstream Processing
         1.1. Vector Amplification and Expansion
         1.2. Vector Recovery/Harvesting
        2. Downstream Processing
         2.1. Purification
         2.2. Fill-finish

  • 9.   Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology

  • 10.   Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others

  • 11.   Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes

  • 12.   North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Merck KGaA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Lonza
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Cobra Biologics Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Brammer Bio
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Waisman Biomanufacturing
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Genezen
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. YPOSKESI
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Advanced BioScience Laboratories, Inc. (ABL, Inc.)
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Novasep Holding S.A.S
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. ATVIO Biotech Ltd.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Vigene Biosciences, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. General Electric Company (GE Healthcare)
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. CEVEC Pharmaceuticals GmbH
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Batavia Biosciences B.V.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Biovian Oy
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Wuxi AppTec Co., Ltd.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. VGXI, Inc.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Paragon Bioservices, Inc.
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Miltenyi Biotec GmbH
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. SIRION Biotech GmbH
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Virovek Incorporation
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. BioNTech IMFS GmbH
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. VIVEbiotech S.L.
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Creative Biogene
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview
        26. Vibalogics GmbH
         26.1. Company Overview
         26.2. Product Portfolio
         26.3. SWOT Analysis
         26.4. Financial Overview
         26.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11